Related Experiment Video
Updated: Jul 15, 2026
10:56
Neural Stem Cell Transplantation in Experimental Contusive Model of Spinal Cord Injury
Published on: December 17, 2014
Plasma brain natriuretic peptide during myeloablative stem cell transplantation
Masayoshi Masuko1, Masahiro Ito, Tori Kurasaki
1Division of Hematology and Cardiology, Graduate School of Medical and Dental Science, Niigata University, Niigata, Japan. mmasuko@med.niigata-u.ac.jp
Internal Medicine (Tokyo, Japan)
|May 3, 2007
Summary
Plasma brain natriuretic peptide (BNP) levels frequently increase after stem cell transplantation (SCT), indicating potential cardiac damage from treatments like chemotherapy and total body irradiation (TBI). Long-term cardiac monitoring is crucial.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Cardiovascular complications are serious risks in stem cell transplantation (SCT).
- Assessing cardiac toxicity from SCT regimens is critical for patient outcomes.
Purpose of the Study:
- To measure plasma brain natriuretic peptide (BNP) concentrations in SCT patients.
- To evaluate the cardiac toxicity associated with SCT preparative regimens.
Main Methods:
- Studied 15 patients undergoing myeloablative allogeneic or autologous SCT.
- Measured plasma BNP using radioimmunoassay before and after SCT.
- Analyzed the impact of chemotherapy and total body irradiation (TBI) on BNP levels.
Main Results:
- Plasma BNP levels increased in 13 of 15 patients post-SCT.
- Higher BNP levels were observed in patients receiving TBI (p=0.01).
- 46.7% of patients showed elevated BNP levels even after 6 months, suggesting subclinical myocardial damage.
Conclusions:
- Elevated plasma BNP post-SCT suggests cardiac damage from preparative regimens.
- The findings highlight the importance of long-term cardiac function evaluation after SCT.
- Subclinical myocardial damage may persist long after treatment completion.
